Ted Steiner

Has grant

Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Contact this professor

ORCID

Google Scholar

Academic Page

About

Professor Ted Steiner is a faculty member at the University of British Columbia, Canada. His research primarily focuses on infectious diseases, adaptive immune responses, and microbial therapeutics, as evidenced by his recent publications on the impacts of COVID-19 vaccines, Clostridioides difficile infections, and immune regulation. He is dedicated to improving patient outcomes in clinical settings through rigorous investigation and innovative healthcare practices.

Recent Grants

Grant: Close

Sex as a Biological Variable Supplement - Neutralizing human-derived single-chain antibodies against SARS-CoV-2

Open Date: 2020-05-01

Close Date: 2021-04-30

Grant: Close

Neutralizing human-derived single-chain antibodies against SARS-CoV-2

Open Date: 2020-04-01

Close Date: 2022-03-31

Grant: Close

A multicentre, double blind, randomized trial comparing lyophilized fecal filtrate to lyophilized stool in treating recurrent Clostridiodes difficile infection

Open Date: 2020-04-01

Close Date: 2024-03-31

Grant: Close

Fecal microbiota transplantation (FMT) for intestinal decolonization of multidrug-resistant opportunistic pathogens

Open Date: 2019-04-01

Close Date: 2024-03-31

Grant: Close

Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection

Open Date: 2018-10-01

Close Date: 2020-09-30

Ted Steiner

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Quantitative analysis of the impact of infectious disease physicians on patients in the emergency department fast-track parenteral antibiotics program

Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study

Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI (Infectious Diseases and Therapy, (2024), 10.1007/s40121-024-01007-z)

Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection

Clostridioides difficile PCR Tcdb Cycle Threshold predicts toxin EIA positivity but not severity of infection

Flagellin-specific human CAR Tregs for immune regulation in IBD

Evading the Toll booth: How “silent” flagellins may bind yet fail to activate TLR5

How to present work productivity loss results from clinical trials for patients and caregivers? A mixed methods approach

Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective

A﻿ TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.

Inhibition of glycogen synthase kinase-3-beta (GSK3β) blocks nucleocapsid phosphorylation and SARS-CoV-2 replication.

An in vitro chronic damage model impairs inflammatory and regenerative responses in human colonoid monolayers

Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B

Recurrent Clostridioides difficile Infection Is Associated With Impaired T Helper Type 17 Immunity to C difficile Toxin B

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial

A method for expansion and retroviral transduction of mouse regulatory T cells.

Collaborators (10)

Antoine Désilets

Michael S. Silverman

François Jean

Benjamin Gaborit

Megan Levings

Wei Zhang

Giacomo Maria Guidelli

Mathias Martins

Yossef Av-Gay

Genelle Lunken

How do I reach out?

Meet Kite AI

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.